Skip to main navigation menu Skip to main content Skip to site footer

Peer reviewed clinical letter

Vol. 145 No. 0304 (2015)

Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report

  • Laura Massobrio
  • Gian Marco Rosa
  • Fabrizio Montecucco
  • Alberto Valbusa
DOI
https://doi.org/10.4414/smw.2015.14048
Cite this as:
Swiss Med Wkly. 2015;145:w14048
Published
11.01.2015

References

  1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
  2. Connolly SJ1, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.
  3. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Anderson K, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35(2):155–69.
  4. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al.; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–420.
  5. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al.; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7.
  6. Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace. 2006;8(4):283–7.
  7. Airaksinen KE, Korkeila P, Lund J, Ylitalo A, Karjalainen P, Virtanen V, et al. Safety of pacemaker and implantable cardioverter-defibrillator implantation during uninterrupted warfarin treatment – the FinPAC study. Int J Cardiol. 2013;168(4):3679–82.
  8. Bhave PD, Knight BP. Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Curr Treat Options Cardiovasc Med. 2013;15(4):450–66.